Tacrolimus vs Opzelura for Vitiligo: Which Is Right for You?
If you are deciding between tacrolimus and Opzelura (ruxolitinib cream) for vitiligo, you are comparing the most-established off-label topical with the first treatment specifically approved by the FDA for vitiligo. They are both effective, they work by different mechanisms, and the right choice depends on factors including the location and extent of your vitiligo, your age, your insurance situation, and your treatment priorities.
Here is a clear comparison of both.
How they work
Tacrolimus is a calcineurin inhibitor. It suppresses T-cell activity by blocking the calcineurin signalling pathway, which reduces the local immune attack on melanocytes in and around vitiligo patches. It was originally developed as an oral immunosuppressant for organ transplant recipients; the topical formulation (Protopic) was approved for eczema and has been used off-label for vitiligo for over two decades.
Opzelura (ruxolitinib cream 1.5%) is a JAK1/2 inhibitor. It blocks the Janus kinase signalling pathway — specifically JAK1 and JAK2 — which is one of the central mechanisms driving the autoimmune attack on melanocytes in vitiligo. Ruxolitinib was already used systemically for blood conditions; the cream formulation was specifically developed and approved for vitiligo (and atopic dermatitis) in adults and children 12 and older.
Evidence base
Tacrolimus
Tacrolimus has been used for vitiligo since the early 2000s. The evidence base is substantial in volume but limited in trial quality. Most studies are small, unblinded, and heterogeneous. Meta-analyses consistently show tacrolimus works — particularly for facial vitiligo — but the magnitude of effect and comparison to other treatments is hard to quantify precisely from this evidence.
For facial vitiligo specifically, tacrolimus 0.1% ointment twice daily produces meaningful repigmentation in a majority of patients over three to six months. Body vitiligo responds less consistently.
Opzelura
Opzelura has a much stronger regulatory evidence base. The TRuE-V phase 3 randomised controlled trials — large, properly blinded, placebo-controlled — established its efficacy clearly. Key findings:
- F-VASI75 (≥75% improvement in facial vitiligo score): achieved by approximately 30% of patients at week 52 with Opzelura, versus under 10% with vehicle
- T-VASI50 (≥50% improvement in total body vitiligo score): significantly higher with Opzelura at 52 weeks
- Statistically significant responses begin appearing from week 24 onwards
The trial design makes Opzelura’s evidence stronger than tacrolimus’s from a regulatory standpoint — though this reflects how recently Opzelura was developed rather than necessarily meaning it is clinically superior in all situations.
Efficacy comparison
No large head-to-head trial has directly compared tacrolimus to Opzelura in vitiligo patients.
Based on available evidence, Opzelura is generally considered more effective — particularly for body vitiligo and for patients with more extensive disease. Tacrolimus has a solid record for facial vitiligo but a weaker record for trunk, arms, and legs.
However, this is not a case where one clearly dominates in every situation. Some patients with facial vitiligo do extremely well on tacrolimus alone. Some patients find the difference in cost or availability tips the decision toward tacrolimus even accepting potentially slower results.
Side effects
Tacrolimus side effects
The most commonly reported side effect is a burning or stinging sensation when tacrolimus is first applied, particularly on inflamed or sun-exposed skin. This typically diminishes after the first few weeks of use.
Long-term safety data for topical tacrolimus is reassuring. Unlike topical corticosteroids, tacrolimus does not cause skin atrophy — which makes it particularly suitable for sensitive areas including the face, eyelids, and genitalia where steroid use is limited.
An older FDA black box warning noted a theoretical cancer risk from topical calcineurin inhibitors based on high-dose animal data and immunosuppressed transplant patients on systemic calcineurin inhibitors. Years of subsequent real-world data have not demonstrated elevated cancer risk from topical tacrolimus at standard doses. Most dermatologists consider this warning overstated for typical clinical use, but it is worth knowing.
Opzelura side effects
Opzelura’s main side effects are local: application-site reactions including itching, redness, or mild irritation in a small percentage of users. Nasopharyngitis (common cold-like symptoms) was slightly elevated in trial participants.
Opzelura carries the class-wide JAK inhibitor warning (shared with oral JAK inhibitors) regarding serious infections, thrombosis, and malignancy. The systemic absorption of topical ruxolitinib is significantly lower than oral formulations, and no increased rates of these serious events were found in clinical trials. The warning is present as a class effect precaution; the real-world risk profile from the cream applied to a limited body surface area is expected to be substantially lower than from oral JAK inhibitors.
Opzelura is not recommended in pregnancy or during breastfeeding. Tacrolimus has a more established (though imperfect) safety record in these contexts — it is generally avoided in pregnancy but the topical data are less alarming than oral immunosuppressants.
Practical considerations
Cost and access
Tacrolimus is generic. It is inexpensive and universally covered by insurance plans that cover dermatology medications. In countries without comprehensive insurance, it is a modest out-of-pocket cost.
Opzelura is brand-name and expensive. In the US, the list price is over $2,000 for a 60g tube. Insurance coverage is improving as its approval for vitiligo becomes established, but prior authorisation is common. Incyte (the manufacturer) has a patient assistance program. Outside the US, availability and pricing vary significantly.
Cost is the most common reason patients choose tacrolimus when Opzelura would otherwise be preferred.
Age restriction
Tacrolimus 0.1% is approved for use in patients 15 and older (0.03% for children 2–14). For vitiligo, it is used off-label so these age thresholds are guides rather than absolute restrictions, but they inform clinical decision-making.
Opzelura is approved for vitiligo in patients 12 and older. For teenagers aged 12–14 specifically, Opzelura has an advantage in its formal approval.
Body surface area limits
Opzelura is not recommended for application to more than 10% of body surface area, primarily because of systemic absorption concerns at higher doses. For patients with very extensive vitiligo (large patches on trunk, limbs), this limits how much area can be treated with Opzelura simultaneously.
Tacrolimus has similar general guidance to avoid high-dose systemic exposure, but it is widely used across larger areas in clinical practice, particularly since its systemic absorption is lower when skin is intact.
Combination with phototherapy
Both tacrolimus and Opzelura have been combined with narrowband UVB phototherapy and both show synergistic benefit. The Opzelura plus NbUVB combination has the strongest recent evidence. Tacrolimus plus NbUVB is the older standard combination, with a reasonable evidence base particularly for facial vitiligo.
Who should use which?
Tacrolimus is likely the better starting choice if:
- Cost or insurance coverage is a significant constraint
- Vitiligo is primarily or exclusively facial
- You are under 12 years old (Opzelura not approved below 12)
- You are pregnant or breastfeeding and topical treatment is still needed
- Your vitiligo involves more than 10% body surface area and you want to treat broadly
Opzelura is likely the better choice if:
- You have insurance coverage or can access the patient assistance program
- Your vitiligo includes body areas (trunk, limbs) where tacrolimus response is weaker
- You want the treatment with the strongest regulatory evidence base for vitiligo
- You are combining with phototherapy and want the most evidence-backed combination
See also the full topical comparison including corticosteroids if you are weighing all three classes, and the vitiligo treatment options comparison for the broader landscape.
